Recombinant Human LGALS13 Protein，His

LGALS13, also known as galectin-13, is a member of the galectin family, which are β-galactoside-binding proteins involved in various biological processes, including cell-cell interaction, inflammation, and immune responses. Research has indicated that LGALS13 plays a significant role in several critical physiological and pathological conditions, such as cancer progression, autoimmune diseases, and infectious diseases. The protein is primarily expressed in immune cells, where it modulates immune responses by influencing the behavior of T cells and macrophages. Furthermore, studies have suggested that LGALS13 may have potential therapeutic applications, particularly in cancer immunotherapy, as it can promote tumor progression by modulating the tumor microenvironment. Understanding the structure and function of recombinant LGALS13 can provide insights into its molecular mechanisms and enhance our ability to manipulate its effects in therapeutic contexts. Thus, the production of recombinant LGALS13 protein has become a focal point of research, aiming to elucidate its biological functions and explore its potential as a biomarker or therapeutic target in various diseases. This recombinant protein serves as a valuable tool for studying its interactions with other biomolecules, evaluating its role in disease models, and developing novel therapeutic strategies that could improve disease outcomes. Overall, LGALS13 remains a promising candidate for further research due to its involvement in crucial biological processes and its potential implications in medical science.